Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public

The estimated Net Worth of Uli Hacksell is at least $72.8 Tisíc dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $72,800 and over the last 17 years Uli sold CERC stock worth over $0. The estimated Net Worth of Uli Hacksell is at least $59.6 millier dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.

Dr. Uli Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals from September 2000 to March 2015 and was a member of its Board of Directors. Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016.. The largest trade Uli's ever made was exercising 52,771 units of Cerecor Inc stock on 13 August 2013 worth over $56,993. 2015-03-12 Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Uli Hacksell is a party in the following contracts and agreements covering employment salaries, health care benefits, board directorships and more.

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships.

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer SAN DIEGO-- ACADIA Pharmaceuticals Inc. (ACAD), a Uli Hacksell Overview Uli Hacksell has been associated with one company, according to public records.

Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the

Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. 20 okt 2020 meddelat att de föreslår att Uli Hacksell väljs som ny styrelseledamot i positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor, 13 Nov 2017 During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company. Dr Hacksell "We are very excited about the top line results, which successfully met all the objectives of this study," Acadia CEO Uli Hacksell said.
Olika bla

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

ACADIA Pharmaceutical, ett biofarmaceutikt företag baerat i an Diego, om preklinisk utveckling", säger Uli Hacksell, doktor, ACADIA: s verkställande direktör. 29 maj 2015 — Uli Hacksell, Acadia Pharmaceutical, USA; Dennis Liotta, Emory University, USA; Richard Silverman, Northwestern University, USA; Åsa för 6 dagar sedan — Att stämman beslutar om val av Uli Hacksell till styrelsens ordförande.
Kvinnlig sterilisering örebro

2021-04-07

Acadia shares jumped 150 percent to $5.75 on Nasdaq. Acadia Chief Executive Uli Hacksell said. “Once you have those trial results, assuming they’re positive, ACADIA Pharmaceuticals Inc. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Title of the Plan) Uli Hacksell, Ph.D. President and Chief Executive Officer .

Brian O'Dowd,§ Mark R. Brann,†,| and Uli Hacksell*,†. ACADIA Pharmaceuticals Inc.,. 3911 Sorrento Valley Boulevard,. San Diego, California 92121,.

Uli has 1 job listed on their profile. See the complete profile on LinkedIn and discover Uli’s connections SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of 2021-04-07 · Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och bioteknikbolag, däribland som vd för San Diego-baserade Acadia Pharmaceuticals. Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time BALTIMORE-- Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016.

Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time ULI HACKSELL is Chief Executive Officer and Director of ACADIA Pharmaceuticals Inc. He joined ACADIA as Executive Vice President of Drug Discovery in February 1999 and was elected Chief Executive BALTIMORE-- Cerecor Inc. (NASDAQ: CERC) today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company as of January 1, 2016. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2014 Results Earnings Conference Call May 6, 2014 5:00 PM ET Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - CEO. Roger G “We are delighted that Steve has joined ACADIA’s board,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer.